Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
A biomarker, endothelial mitochondrial function, may be useful for early identification of newborn babies at risk for lung disease and could enable novel therapy approaches.
Successful Phase III trials at UAB contributed to the development of a novel “corrector-potentiator” combination drug therapy for cystic fibrosis patients.
These scientifically diverse researchers deliver lectures at American Society for Microbiology Branch meetings throughout the United States.
A UAB symposium on cardiovascular tissue engineering brought together some of the best in the business in this rapidly developing field of translational medicine.
The first target for the UAB spinoff Incysus Ltd. will be glioblastoma. Incysus has just received a European patent for its innovative approach to fighting cancer.
Knowledge from this study and others may help physicians boost healing and prevent heart failure in patients after a heart attack.
Chemistry and philosophy classes, a neuro-oncology lab, hospital volunteer work, and the TKE fraternity were all UAB steppingstones for the first-generation American and Florence High School graduate. 
Mitochondrial DNA moving to the nucleus contributes to genomic instability in cancer cells, and a novel Fiber-FISH technique can rapidly map the mitochondrial DNA insertions in nuclear genomes.
These microcarriers may offer an entirely different approach to treating solid human tumors of numerous pathologic subtypes by delivering their encapsulated drug cargo to a tumor and protecting against collateral tissue damage.
UAB assays enabled the first genomewide association study of IgA1 O-glycosylation aberrancy in IgA nephropathy, a disease that frequently causes kidney failure.